Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 3/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15375292 | 0.98 | TSHR (0.36) | CETPCNR1CNR2TSHRTHRB | |
| SCHEMBL6062501 | 0.98 | TSHR (0.36) | CETPCNR1CNR2TSHRTHRB | |
| SCHEMBL10685233 | 0.98 | TSHR (0.36) | CETPCNR1CNR2TSHRTHRB | |
| SCHEMBL6061239 | 0.98 | TSHR (0.36) | CETPCNR1CNR2TSHRTHRB | |
| SCHEMBL1485789 | 0.98 | TSHR (0.36) | CETPCNR1CNR2TSHRTHRB | |
| SCHEMBL1485626 | 0.98 | TSHR (0.36) | CETPCNR1CNR2TSHRTHRB | |
| SCHEMBL6063488 | 0.98 | TSHR (0.36) | CETPCNR1CNR2TSHRTHRB | |
| SCHEMBL6061746 | 0.98 | TSHR (0.36) | CETPCNR1CNR2TSHRTHRB | |
| SCHEMBL6061592 | 0.98 | TSHR (0.36) | CETPCNR1CNR2TSHRTHRB | |
| SCHEMBL9211045 | 0.98 | TSHR (0.36) | CETPCNR1CNR2TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 627 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023201303-A2 | SYSTEMS AND METHODS TO AUTOMATICALLY ADMINISTER A PSYCHOACTIVE SUBSTANCE TO AN AIRWAY OF A USER BASED ON A DETECTED EVENT OR CONDITION | Green Sky Creations, LLC (US) | 2023-10-19 | — | — | WO | claimed |
| WO-2023154450-A2 | (AMPA-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | WO | claimed |
| EP-3278100-B1 | METHODS AND USES COMPRISING SOLID PHASE EXTRACTION, DERIVATIZATION WITH CROWN ETHERS, AND MASS SPECTROMETRY | TECAN SP INC (US) | 2023-06-14 | — | — | EP | claimed |
| EP-3909585-A1 | DOSING REGIMEN ASSOCIATED WITH LONG ACTING INJECTABLE PALIPERIDONE ESTERS | Janssen Pharmaceutica NV (BE) | 2021-11-17 | — | — | EP | claimed |
| US-20200384188-A1 | SYSTEMS, DEVICES, FORMULATIONS AND METHODS FOR CONTROLLED DRUG DELIVERY | BEXSON BIOMEDICAL, INC. | 2020-12-10 | — | — | US | claimed |
| EP-3710079-A1 | SYSTEMS, DEVICES, FORMULATIONS AND METHODS FOR CONTROLLED DRUG DELIVERY | Bexson Biomedical, Inc. (US) | 2020-09-23 | — | — | EP | claimed |
| US-20190293667-A1 | Solid Phase Extraction, Derivatization with Crown Ethers, and Mass Spectrometry, Methods, Reagents and Kits | TECAN SP, INC. (US) | 2019-09-26 | — | — | US | claimed |
| US-10267775-B2 | Extraction, derivatization, and quantification of analytes | TECAN SP, INC. (US) | 2019-04-23 | — | — | US | claimed |
| EP-3278100-A1 | SOLID PHASE EXTRACTION, DERIVATIZATION WITH CROWN ETHERS, AND MASS SPECTROMETRY, METHODS, REAGENTS AND KITS | Tecan SP, Inc. (US) | 2018-02-07 | — | — | EP | claimed |
| US-20170128451-A1 | DOSING REGIMEN ASSOCIATED WITH LONG ACTING INJECTABLE PALIPERIDONE ESTERS | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-11 | — | — | US | claimed |
| EP-1009403-A1 | METHOD FOR TREATING SCHIZOPHRENIA | ELI LILLY AND COMPANY (US) | 2000-06-21 | — | — | EP | claimed |
| WO-1998046225-A1 | METHOD FOR TREATING SCHIZOPHRENIA | ELI LILLY AND COMPANY (US) | 1998-10-22 | — | — | WO | claimed |
| WO-1998046226-A1 | METHOD FOR TREATING SCHIZOPHRENIA | ELI LILLY AND COMPANY (US) | 1998-10-22 | — | — | WO | claimed |
| US-5817657-A | USING 2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-10H-THIENO(2,3-B)(1,5)BENZ ODIAZEPINE | ELI LILLY AND COMPANY (US) | 1998-10-06 | — | — | US | claimed |
| US-5801171-A | Use of 3, 5-diamino-6-(2,3-dichlorophenyl)-1, 2, 4-triazine isethionate for the treatment and prevention of dependence; tolerance and sensitization of drugs | GLAXO WELLCOME INC (US) | 1998-09-01 | — | — | US | claimed |
| WO-1998019674-A2 | A METHOD FOR TREATING TENSION-TYPE HEADACHE | HEAD EXPLORER APS (DK) | 1998-05-14 | — | — | WO | claimed |
| EP-0396734-B1 | PHARMACEUTICAL COMPOSITIONS FOR NEURO PROTECTION CONTAINING ARYLCYCLOHEXYLAMINES | CENTRE NAT RECH SCIENT (FR) | 1994-06-15 | — | — | EP | claimed |
| US-5179109-A | Neuroprotection | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1993-01-12 | — | — | US | claimed |
| EP-0396734-A1 | PHARMACEUTICAL COMPOSITIONS FOR NEURO PROTECTION CONTAINING ARYLCYCLOHEXYLAMINES. | CENTRE NAT RECH SCIENT (FR) | 1990-11-14 | — | — | EP | claimed |
| WO-1990005524-A2 | PHARMACEUTICAL COMPOSITIONS FOR NEURO PROTECTION CONTAINING ARYLCYCLOHEXYLAMINES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1990-05-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170128451-A1 | DOSING REGIMEN ASSOCIATED WITH LONG ACTING INJECTABLE PALIPERIDONE ESTERS | LPXN, GLP1R, SSTR4 | CETP 743/4885CNR1 1170/4885CNR2 1470/4885 |
| US-20190293667-A1 | Solid Phase Extraction, Derivatization with Crown Ethers, and Mass Spectrometry, Methods, Reagents and Kits | CYP2C8, CES2, UGT1A8 | CETP 54/4885CNR1 822/4885CNR2 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.